SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175179.
  • 2
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165176.
  • 3
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu K, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 4
    Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:2519025194.
  • 5
    The American Society for Bone Miner Research President's Committee on Nomenclature 2000 Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J Bone Miner Res 15:22936.
  • 6
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315323.
  • 7
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309319.
  • 8
    Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R 2000 Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106:12291237.
  • 9
    Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P 2001 RANKL and OPG expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:2065920672.
  • 10
    Myers D, Collier F, Minkin C, Wang H, Holloway W, Malakellis M, Nicholson G 1999 Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 463:295300.
  • 11
    Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan CR, Boyle WJ, Lacey DL 2000 Characterization of osteoclast precursors in human blood. Br J Haematol 111:501512.
  • 12
    Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527538.
  • 13
    Lacey DL, Tan H, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess T, Boyle WJ, Polverino A 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435448.
  • 14
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ 1998 TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts. J Exp Med 188:9971001.
  • 15
    Nakagawa N, Kinosaki M, Yamaguch K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395400.
  • 16
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:35403545.
  • 17
    Dougall WC, Glaccum M, Charrier K, Brasel K, Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson DM, Morrissey PJ, Peschon JJ, Schuh J 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13:24122424.
  • 18
    Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:15661571.
  • 19
    Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T 1999 Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434442.
  • 20
    Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL 2000 TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:14811488.
  • 21
    Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y 2001 Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276:563568.
  • 22
    Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T 1998 Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:87998805.
  • 23
    Siebenlist U, Franzoso G, Brown K 1994 Structure, regulation and function of NF-κB. Ann Rev Cell Bio 10:405455.
  • 24
    Baeuerle P, Baltimore D 1996 NF-κB: Ten years after. Cell 87:1320.
  • 25
    Baldwin A 2001 The transcription factor NF-κB and human disease. J Clin Invest 107:36.
  • 26
    Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S 1995 Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 9:27232735.
  • 27
    Baldwin A 1998 The NF-κB and IκB proteins: New discoveries and insights. Ann Res Immunol 14:649683.
  • 28
    Karin M, Ben-Neriah Y 2000 Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Ann Rev Immunol 18:621663.
  • 29
    Hall T, Schaeublin M, Jeker H, Fuller K, Chambers TJ 1995 The role of reactive oxygen intermediates in osteoclastic bone resorption. Biochem Biophys Res Commun 207:280287.
  • 30
    Jimi E, Ikebe T, Takahashi N, Hirata M, Suda T, Koga T 1996 Interleukin-1 α activates an NF-κB like factor in osteoclast-like cells. J Biol Chem 271:46054608.
  • 31
    Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S 1997 NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 410:297300.
  • 32
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-κB in osteoclast and B cell development. Genes Dev 11:34823496.
  • 33
    Iotsova V, Caamano J, Loy J, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3:12851289.
  • 34
    Beg AA, Baltimore D 1996 An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782784.
  • 35
    Wang C, Mayo M, Baldwin A 1996 TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274:784787.
  • 36
    Barnes PJ, Karin M 1997 Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:10661071.
  • 37
    Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T 1988 Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:13731382.
  • 38
    Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P 1993 Osteopetrosis in src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90:44854489.
  • 39
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:11321136.
  • 40
    UY HL, Dallas M, Calland JW, Boyce BF, Mundy GR, Roodman D 1995 Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage. J Bone Miner Res 10:295301.
  • 41
    Young F, Ardman B, Shinkai Y, Lansford R, Blackwell TK, Mendelsohn M, Rolink A, Melchers F, Alt FW 1994 Influence of immunoglobulin heavy- and light-chain expression on B-cell differentiation. Genes Dev 8:10431057.
  • 42
    Boyce BF, Wright K, Reddy SV, Koop BA, Story B, Devlin R, Leach RJ, Roodman GD, Windle JJ 1995 Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Endocrinology 136:57515759.
  • 43
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:14781487.
  • 44
    Roodman G 1999 Cell biology of the osteoclast. Exp Hematol 27:12291241.
  • 45
    Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Nerlah Y, Baeuerle PA 1993 Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365:182185.
  • 46
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:12601268.
  • 47
    Pacifici R 1998 Cytokines, estrogen, and postmenopausal osteoporosis—the second decade. Endocrinology 139:26592661.
  • 48
    Jilka RL 1998 Cytokines, bone remodeling, and estrogen deficiency: A 1998 update. Bone 23:7581.
  • 49
    Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B 1996 Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 64:23712380.
  • 50
    Kollias G, Douni E, Kassiotis G, Kontoyiannis D 1999 The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58:I32I39.
  • 51
    Kudo O, Sabokbar A, Fujikawa Y, Torisu T, Athanasou N 2001 I L-6 induces human osteoclast formation and bone resorption independent of RANK/RANKL interaction. J Bone Miner Res 16:1175.
  • 52
    Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S 2000 The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 19:63516360.